Original Contributions |
From the Departments of Anesthesiology and Pharmacology, Mayo Clinic, Rochester, Minn (Z.S.K., A.S.); and the Laboratory of Cell Biology, National Institute of Mental Health, National Institutes of Health, Bethesda, Md (S.M.).
Correspondence to Zvonimir S. Katusic, MD, PhD, Department of Anesthesiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.
| Abstract |
|---|
|
|
|---|
(TNF-
), interferon-
(INF-
), and interleukin-1ß
(IL-1ß) stimulate tetrahydrobiopterin synthesis by increasing
expression of GTP cyclohydrolase I mRNA in endothelial
cells. The relative reverse transcription polymerase chain reaction was
used to quantify expression of GTP cyclohydrolase I mRNA in cultured
human umbilical vein endothelial cells. Nuclear run-on
assay was performed to determine the transcription rate of GTP
cyclohydrolase I gene. GTP cyclohydrolase I enzymatic activity and
production of tetrahydrobiopterin were measured in cell
extracts. After incubation with TNF-
(2 µg/mL), INF-
(200
U/mL), and IL-1ß (5 U/mL) for 24 hours, significantly increased
expression of GTP cyclohydrolase I mRNA was detected. Cytokines
increased the transcription rate of GTP cyclohydrolase I 3.6-fold. This
increase was associated with increased GTP cyclohydrolase I enzymatic
activity and elevation of intracellular levels of tetrahydrobiopterin.
An RNA synthesis inhibitor, actinomycin D (2 µg/mL),
inhibited cytokine-induced expression of GTP cyclohydrolase
I gene. A protein synthesis inhibitor, cycloheximide (0.5
µg/mL), did not affect expression of GTP cyclohydrolase I mRNA but
blocked the increase in enzyme activity, as well as production
of tetrahydrobiopterin. Incubation of endothelial cells
for 24 hours in the presence of 8-bromoadenosine 3':5'-cyclic
monophosphate (10-3 mol/L) did not affect expression of
GTP cyclohydrolase I mRNA. These results demonstrate that in vascular
endothelial cells, cytokines increase
production of tetrahydrobiopterin by stimulating expression of
GTP cyclohydrolase I gene. This effect is apparently due to increased
transcription rather than stabilization of mRNA. Regulation of GTP
cyclohydrolase I gene expression by cytokines may play an
important role in control of endothelial nitric
oxide synthesis.
Key Words: nitric oxide tetrahydrobiopterin tumor necrosis factor-
interferon-
interleukin-1ß
| Introduction |
|---|
|
|
|---|
,
INF-
, and IL-1ß stimulate production of
tetrahydrobiopterin, with subsequent elevation of
endothelial nitric oxide synthase
activity.2 3 This stimulatory effect is
apparently mediated by increased enzymatic activity of GTP
cyclohydrolase I, which is the rate-limiting enzyme for synthesis of
tetrahydrobiopterin.2 Long-term regulation of GTP
cyclohydrolase I mRNA levels in endothelial cells has
not been studied previously. Therefore, the present study was
designed to determine whether cytokines increase
tetrahydrobiopterin levels by stimulating expression of the GTP
cyclohydrolase I gene in cultured HUVECs. | Methods |
|---|
|
|
|---|
500 000 cells
per ampuole). They were grown in gelatin-coated flasks in optimized
endothelial growth medium supplied by Clonetics. The
cells were passaged by exposure to trypsin/EDTA for about 120 seconds
in HEPES-buffered saline and reseeded in T-175 flasks. Cells grew to
confluence after about 5 days in 95% humidified air/5%
CO2 at 37°C and were used up to passage level
six.
Quantification of mRNA Levels
Total RNA was isolated by RNA STAT-60 kit (Tele-Test
"B"/Inc). Integrity of the isolated RNA was evaluated by
visualizing the ethidium bromidestained nucleic acids after
electrophoresis through 1% agarose gel. RNA concentrations were
calculated from the optical density at 260 nm, and the purity was
determined by
A260/A280.
Cellular RNA (1, 2, and 4 µg) was reverse transcribed in a 20-µL
reaction mixture containing 200 U reverse transcriptase (Superscript
GIBCO-BRL, Life Technologies, Inc). For PCR amplification, each 25-µL
reaction mixture contained 1 µL of cDNA derived from 1 µg of total
RNA, 1x106 cpm of labeled 5'-primer, 10 pmol of
each unlabeled primer, 2 U of Taq DNA polymerase, 2.5 µL
of 10x buffer provided with Taq DNA polymerase, and optimal
concentration of MgCl2 (3.5 mmol/L). The PCR
conditions were as follows: denaturation for 30 seconds at 94°C,
annealing for 30 seconds at 59°C, and extension for 30 seconds at
72°C. Oligo 4.0 software was used to design primers and determine
optimal conditions for PCR reaction4 (Table 1
).
|
Incorporation of 32Pend-labeled primers of known specific radioactivity into PCR product was measured as a function of PCR cycle number. The total amount of radioactivity incorporated from end-labeled primer is proportional to product copy number and is independent of product size. Sense primers were labeled with 32P using T4 polynucleotide kinase. Unincorporated isotope was removed by using Nick columns (Pharmacia), and percent incorporation was determined, permitting calculation of the specific radioactivity of the radiolabeled primers.
The PCR product was separated from unincorporated primer by electrophoresis through 1.5% agarose gels. The band migrating at the predicted size was excised, and radioactivity was determined by Cerenkov counting. The point in the exponential amplification range for comparison was selected by inspection of semilogarithmic plots of counts per minute versus cycle number.
Subcloning and DNA Sequencing
DNA obtained with PCR was extracted using Geneclean (Bio 101)
and subcloned in pCR-Script Sk(+) cloning vector (Stratagene), which is
based on pBluescript II Sk(+). Phagemid DNA was isolated, and
double-stranded DNA was sequenced using Sequenase 2.0 (United States
Biochemical) with primers complementary to the T3 and KS promoters in
pBluescript.5
Estimates of Transcription Rate
Nuclear run-on assays were performed using a modified method
described by Greenberg and Bender.6 Cells and
solutions were maintained on ice throughout the procedure. Briefly,
endothelial cells were trypsinized and
centrifuged at 1500 rpm for 5 minutes. Cells were washed twice
in phosphate-buffered saline followed by a single wash in resuspension
buffer containing 10 mmol/L Tris, 10 mmol/L NaCl, and 3
mmol/L MgCl2. Cell pellets were resuspended in a
small volume of resuspension buffer. Cells were lysed by the addition
of 4 vol resuspension buffer containing 0.125% NP-40. Nuclei were
isolated by centrifugation as above. Nuclear pellets
were suspended in storage buffer containing 50 mmol/L Tris, 5
mmol/L MgCl2, 100 mmol/L EDTA, and 40%
glycerol and stored under liquid nitrogen until further
analysis.
In vitro transcription was performed with 25 to
44x106 nuclei. The reaction was performed in
25 mmol/L Tris, 12.5 mmol/L MgCl2,
750 mmol/L KCl, 1.25 mmol/L each ATP, CTP, and GTP, and 30
µL of [
32P]UTP (3000 Ci/mmol/L) at 30°C
for 30 minutes. Identical numbers of nuclei were used from control and
cytokine-treated cells. The reaction was stopped by the
addition of RNase-free DNase I in HSB buffer (0.5 mol/L NaCl, 50
mmol/L MgCl2, 2 mmol/L
CaCl2, and 10 mmol/L Tris) for 10 minutes at
30°C. The nuclei were lysed in 10% SDS, 50 mmol/L EDTA, and
100 mmol/L Tris and treated with 200 µg/mL proteinase K for 45
minutes at 42°C. RNA was phenol/chloroform extracted and precipitated
with 3 mol/L NH4OAC and equal volume of
isopropanol. Centrifuged RNA pellets were suspended in TE
buffer (10 mmol/L Tris and 1 mmol/L EDTA) and separated from
unincorporated nucleotides on a Micron-100 column (Amicon,
Inc). RNA was denatured in 0.2 mol/L NaOH, neutralized with 0.24 mol/L
HEPES, and precipitated in ethanol overnight at -20°C. RNA pellets
were suspended in TES solution (10 mmol/L TES, 10 mmol/L
EDTA, and 0.2% [wt/vol] SDS), and 5 µL was used to determine
counts per minute.
Linearized cDNA (5 µg each) for human GTP cyclohydrolase I (a generous gift of Dr T. Nagatsu), GAPDH (500 bp cloned into pCRII, Invitrogen, a gift from Dr Emanuel Strehler), and plasmid pRc/CMV (Invitrogen) were immobilized onto supported nitrocellulose (GIBCO-BRL, Life Technologies, Inc) by a slot-blot apparatus (Schleicher & Schuell). Membranes were prehybridized overnight at 65°C in 10 mmol/L TES, 10 mmol/L EDTA, 0.2% (wt/vol) SDS, 0.3 mol/L NaCl, 2x Denhardt's solution, and 0.25 mg/mL yeast tRNA. Equal counts (5 to 10x106 cpm/mL) of radiolabeled transcripts from control and cytokine-treated cells were added to the membranes in fresh hybridization solution and hybridized for 48 to 72 hours at 65°C. The membranes were washed three times in 2x SSC and 0.1% SDS and twice in 0.1x SSC and 0.1% SDS for 30 minutes at 65°C. The membranes were exposed to autoradiography at -80°C. Autoradiograms were scanned on a UMAX UC1260 flatbed scanner (UMAX Data Systems, Inc), using Adobe Photoshop 3.0 software. Densitometric analysis was performed using NIH Image 1.61 software.
Determination of Tetrahydrobiopterin and GTP Cyclohydrolase I
Activity in Cell Extracts
After incubation with different drugs, cells were harvested with
trypsin, washed with PBS, pelleted by centrifugation,
and stored frozen at -80°C. Measurements of tetrahydrobiopterin were
performed with high-performance liquid
chromatography analysis after oxidation by
MnO2 or iodine as previously
described.7 GTP cyclohydrolase I activity was
determined by high-performance liquid
chromatography measurements of neopterin released from
dihydroneopterin triphosphate after oxidation and phosphatase treatment
by minor modification of previously described
methods.2
Drugs
The following drugs were used: actinomycin D, 8-bromo-cAMP,
cycloheximide (Sigma Chemical Co), INF-
, IL-1ß, and TNF-
(Collaborative Biomedical Products).
Calculations and Statistics
All experiments were conducted with cells obtained from at least
three different donors. In each set, n represents the number of
experiments. Statistical evaluation was done by paired Student's
t test. Means were considered significantly different at
P<.05.
| Results |
|---|
|
|
|---|
Quantitative analysis of electrophoretically isolated GTP
cyclohydrolase I and GAPDH PCR products showed exponential
amplification of the semilogarithmic plot of counts per minute
incorporated versus cycle number (Fig 1
).
Thirty and 25 cycles (middle portion of exponential amplification) were
chosen for further studies of GTP cyclohydrolase I and GAPDH gene
expression, respectively.
|
Incubation of HUVECs for 24 hours in the presence of TNF-
(2
µg/mL), IFN-
(200 U/mL), and IL-1ß (5 U/mL) significantly
increased expression of GTP cyclohydrolase I mRNA (Fig 2
). Induction of GTP cyclohydrolase I
mRNA was apparent by 3 hours, peaked at 8 hours, and was sustained at
high levels for at least 24 hours (Fig 3
). In contrast, the same cocktail of
cytokines did not affect expression of the GAPDH gene (Figs 2
and 3
). Cytokines also stimulated GTP cyclohydrolase I
enzymatic activity and production of tetrahydrobiopterin (Fig 4
).
|
|
|
Actinomycin D (2 µg/mL) inhibited cytokine-induced
expression of GTP cyclohydrolase I in HUVECs (Fig 4
). In contrast,
cycloheximide (0.5 µg/mL) did not block the stimulatory effect of
cytokines (Fig 5
). Actinomycin D
and cycloheximide abolished and significantly reduced
cytokine-induced production of tetrahydrobiopterin,
respectively (Fig 6
).
|
|
To determine whether the response of GTP cyclohydrolase I to
cytokines involved change in mRNA transcription, nuclear run-on
experiments were performed. Run-on transcription assays demonstrated
that the transcriptional rate of GTP cyclohydrolase I was increased
3.6±0.6-fold (n=7; P<.05) after 24 hours exposure to
cytokines (Fig 7
). In contrast,
only 1.6±0.2-fold increase in transcriptional rate of GAPDH was
detected (n=7; P>.05). Nonspecific hybridization was ruled
out by the absence of signals on nylon membranes slot blotted with a
plasmid pRc/CMV.
|
Incubation of endothelial cells for 24 hours with
8-bromo cAMP (10-3 mol/L) did not affect
expression of GTP cyclohydrolase I or GAPDH mRNA (Table 2
).
|
| Discussion |
|---|
|
|
|---|
Two types of RT-PCR assays are currently in use. In the quantitative RT-PCR assay, known amounts of synthetic RNA (or cDNA) are coamplified in the same tube as a sample of cellular RNA. The quantitative RT-PCR assay allows the determination of the number of mRNA molecules per cell. However, in the relative RT-PCR assay (used in the present study), a housekeeping gene (GAPDH) and the experimental gene product (GTP cyclohydrolase I) are amplified in separate tubes. The relative RT-PCR method allows the determination of differences in mRNA levels between different samples.10 Extensive analysis of parameters involved in the quantitative RT-PCR assay clearly demonstrated that the relative and quantitative RT-PCR assays yielded comparable results.11 To use the relative RT-PCR technique to measure GTP cyclohydrolase I cDNA, we determined the number of PCR cycles that were in the exponential range of amplification. Most importantly, the major advantage of this approach was that it enabled us to study expression of low abundant GTP cyclohydrolase I mRNA in endothelial cells.
Cytokines significantly increased transcription rate of GTP cyclohydrolase I by 3.6-fold. This finding is in contrast to the levels of GTP-cyclohydrolase I mRNA, which were increased fourfold to fivefold by cytokines. Although it is very difficult to compare semiquantitative data obtained with PCR and run-on assay, our findings raise the possibility that cytokines may have an additional effect on GTP cyclohydrolase I mRNA stability. Further studies are needed to characterize contribution of this mechanism to cytokine-induced increase in expression of GTP cyclohydrolase I gene in endothelial cells.
The ability of the RNA synthesis inhibitor actinomycin D12 to inhibit cytokine-induced increase in expression of GTP cyclohydrolase I mRNA supports our conclusion that increased transcription of mRNA is responsible for the effect of cytokines. Treatment with actinomycin D also abolished the stimulatory effect of cytokines on production of tetrahydrobiopterin, reinforcing the concept that increased transcription of GTP cyclohydrolase I is an important regulatory mechanism responsible for increased biosynthesis of tetrahydrobiopterin.
Increased expression of GTP cyclohydrolase I mRNA in response to long-term treatment with cytokines appears to be independent of protein synthesis. Unlike results in cultured smooth muscle cells,13 the protein synthesis inhibitor cycloheximide did not enhance expression of the GTP cyclohydrolase I gene in endothelial cells. These findings suggest that different control mechanisms may be responsible for regulation of GTP cyclohydrolase I gene expression in vascular endothelium and smooth muscle. In contrast, cycloheximide inhibited production of tetrahydrobiopterin in endothelial cells, confirming that increased biosynthesis of tetrahydrobiopterin is dependent on protein synthesis. This finding is in agreement with a previous report on inhibition of tetrahydrobiopterin synthesis by cycloheximide in cultured dopamine neurons3 and most likely reflects reduction in de novo synthesis of GTP cyclohydrolase I protein.
Several previous studies indicated that cellular levels of cAMP may play an important role in regulation of tetrahydrobiopterin biosynthesis.14 15 16 In the pineal gland, receptor-mediated increase in cAMP levels inhibits synthesis of tetrahydrobiopterin.15 In contrast, in adrenal medullary cells and dopamine neurons, as well as in cultured rat aortic smooth muscle cells, GTP cyclohydrolase I enzymatic activity and tetrahydrobiopterin content are elevated by agents that increase intracellular levels of cAMP.14 16 The precise cAMP-dependent mechanisms responsible for these effects have not been identified. It is important to note that stimulation of vascular smooth muscle cells with forskolin induced expression of GTP cyclohydrolase I mRNA.16 In the present study, a 10-3 mol/L concentration of 8-bromo-cAMP did not affect expression of the GTP cyclohydrolase I gene. We did not measure GTP cyclohydrolase I enzymatic activity or production of tetrahydrobiopterin in cells treated with cAMP analogue; therefore, we cannot rule out that cAMP may affect biosynthesis of tetrahydrobiopterin. However, our results suggest that in vascular endothelium, cAMP alone does not induce expression of GTP cyclohydrolase I mRNA.
In rats treated with lipopolysaccharide, increased expression
of GTP cyclohydrolase I mRNA has been detected in lung, heart, and
liver.9 18 These studies demonstrated that
upregulation of GTP cyclohydrolase I gene expression does occur in
vivo. More importantly, it appears that availability of
tetrahydrobiopterin is a limiting factor in nitric oxide
production after induction of nitric oxide synthase with
lipopolysaccharide. Interestingly, glucocorticoids have an
inhibitory effect on GTP cyclohydrolase I mRNA
expression.9 This effect significantly
contributes to reduction of nitric oxide formation in animals treated
with lipopolysaccharide.9 The promoter
region of the rat GTP cyclohydrolase I gene has been cloned, and it
contains sites potentially responsive to nuclear factor-
B, IFN-
,
nuclear factor IL6, and Activator Protein1
(AP-1).19 The structure of the gene promoter is
certainly consistent with results obtained with
cytokines in the present study and may explain the reported
ability of dexamethasone to inhibit induction of GTP
cyclohydrolase I.
The major function of tetrahydrobiopterin synthesized in arterial wall is to support the activity of nitric oxide synthase and production of nitric oxide. Previous studies on cultured HUVECs demonstrated that availability of tetrahydrobiopterin may regulate activity of the constitutive (endothelial) isoform of nitric oxide synthase.2 3 Furthermore, in isolated cerebral arteries, increased intracellular concentrations of tetrahydrobiopterin may augment endothelium-dependent relaxations mediated by nitric oxide.20 These findings and the results of the present study suggest that in endothelial cells, regulation of GTP cyclohydrolase I gene expression and tetrahydrobiopterin biosynthesis may have an important role in control of nitric oxide production.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received May 3, 1996; accepted September 8, 1997.
| References |
|---|
|
|
|---|
2. Rosenkranz-Weiss P, Sessa WC, Milstien S, Kaufman S, Watson CA, Pober JS. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. J Clin Invest. 1994;93:22362243.
3.
Werner-Felmayer G, Werner ER, Fuchs D, Hausen A,
Reibnegger G, Schmidt K, Weiss G, Wachter H. Pteridine biosynthesis in
human endothelial cells. J Biol Chem. 1993;268:18421846.
4. Katusic ZS, Stelter AM. Type I inositol-triphosphate receptor gene is alternatively spliced in human cerebral arteries. Biochem Biophys Res Commun. 1995;214:803809.[Medline] [Order article via Infotrieve]
5. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989: chap 13, 4277.
6. Greenberg ME, Bender TP, Identification of newly transcribed RNA. In: Ausubel FA, Brent R, Kingston RE, Moore DD, Seideman JG, Smith JA, Strohl K, eds. Current Protocols in Molecular Biology. New York, NY: John Wiley & Sons, Inc, 1997: chap 10.
7. Fukushima T, Nixon JC. Analysis of reduced forms of biopterin in biological fluids and tissues. Anal Biochem. 1980;102:176188.[Medline] [Order article via Infotrieve]
8. Togari A, Ichinose H, Matsumoto S, Fujita K, Nagatsu T. Multiple mRNA forms of human GTP cyclohydrolase I. Biochem Biophys Res Commun. 1992;187:359365.[Medline] [Order article via Infotrieve]
9.
Simmons WW, Ungureanu-Longrois D, Smith GK, Smith TW, Kelly
RA. Glucocorticoids regulate inducible nitric oxide synthase by
inhibiting tetrahydrobiopterin synthesis and L-arginine
transport. J Biol Chem.. 1996;271:2392823937.
10. Chen D, Klebe RJ. Controls for validation of relative reverse transcriptionpolymerase chain reaction assays. PCR Methods Appl. 1993;3:127129.[Medline] [Order article via Infotrieve]
11.
Bouaboula M, Legoux P, Pessegue B, Delpech B, Dumong X,
Piechaczyk M, Casellas P, Shire D. Standardization of mRNA titration
using a polymerase chain reaction method involving coamplification with
a multispecific internal control. J Biol Chem. 1992;267:2183021838.
12. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Molecular Biology of the Cell. 2nd ed. New York, NY: Garland Publishing, Inc; 1989:218.
13. Hattori Y, Gross SS. GTP cyclohydrolase I mRNA is induced by LPS in vascular smooth muscle: characterization, sequence and relationship to nitric oxide synthase. Biochem Biophys Res Commun. 1993;195:435441.[Medline] [Order article via Infotrieve]
14. Abou-Donia MM, Wilson SP, Zimmerman TP, Nichol CA, Viveros OH. Regulation of guanosine triphosphate cyclohydrolase and tetrahydrobiopterin levels and the role of the cofactor in tyrosine hydroxylation in primary cultures of adrenomedullary chromaffin cells. J Neurochem. 1986;46:11901199.[Medline] [Order article via Infotrieve]
15.
Kapatos G, Kaufman S, Weller JL, Klein DC. Biosynthesis
of biopterin: adrenergic cyclic adenosine
monophosphate-dependent inhibition in the pineal gland.
Science. 1981;213:11291131.
16. Scott-Burden T, Elizondo E, Ge T, Boulanger CM, Vanhoutte PM. Simultaneous activation of adenylyl cyclase and protein kinase C induces production of nitric oxide by vascular smooth muscle cells. Mol Pharmacol. 1994;46:274282.[Abstract]
17.
Zhu M, Hirayama K, Kapatos G. Regulation of
tetrahydrobiopterin biosynthesis in cultured dopamine neurons by
depolarization and cAMP. J Biol Chem. 1994;269:1182511829.
18. Hattori Y, Oka M, Kasai K, Nakanishi N, Shimoda SI. Lipopolysaccharide treatment in vivo induces tissue expression of GTP cyclohydrolase I mRNA. FEBS Lett. 1995;368:336338.[Medline] [Order article via Infotrieve]
19. Hattori Y, Kasai K, Hattori S, Shimoda S, Nakanishi N, Gross SE. Endothelium.. 1995;3:S28. Abstract.
20.
Tsutsui M, Milstien S, Katusic ZS. Effect of
tetrahydrobiopterin on endothelial function in canine
middle cerebral arteries. Circ Res. 1996;79:336342.
This article has been cited by other articles:
![]() |
M. J. Crabtree, A. L. Tatham, A. B. Hale, N. J. Alp, and K. M. Channon Critical Role for Tetrahydrobiopterin Recycling by Dihydrofolate Reductase in Regulation of Endothelial Nitric-oxide Synthase Coupling: RELATIVE IMPORTANCE OF THE DE NOVO BIOPTERIN SYNTHESIS VERSUS SALVAGE PATHWAYS J. Biol. Chem., October 9, 2009; 284(41): 28128 - 28136. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Tatham, M. J. Crabtree, N. Warrick, S. Cai, N. J. Alp, and K. M. Channon GTP Cyclohydrolase I Expression, Protein, and Activity Determine Intracellular Tetrahydrobiopterin Levels, Independent of GTP Cyclohydrolase Feedback Regulatory Protein Expression J. Biol. Chem., May 15, 2009; 284(20): 13660 - 13668. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Peterson, L. V. d'Uscio, S. Cao, X.-L. Wang, and Z. S. Katusic Guanosine Triphosphate Cyclohydrolase I Expression and Enzymatic Activity Are Present in Caveolae of Endothelial Cells Hypertension, February 1, 2009; 53(2): 189 - 195. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Sasaki, T. Yamashita, T. Takaya, M. Shinohara, R. Shiraki, M. Takeda, N. Emoto, A. Fukatsu, T. Hayashi, K. Ikemoto, et al. Augmentation of Vascular Remodeling by Uncoupled Endothelial Nitric Oxide Synthase in a Mouse Model of Diabetes Mellitus Arterioscler Thromb Vasc Biol, June 1, 2008; 28(6): 1068 - 1076. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nandi, P. Kelly, P. Vallance, and J. Leiper Over-expression of GTP-cyclohydrolase 1 feedback regulatory protein attenuates LPS and cytokine-stimulated nitric oxide production Vascular Medicine, February 1, 2008; 13(1): 29 - 36. [Abstract] [PDF] |
||||
![]() |
C. Antoniades, C. Shirodaria, M. Crabtree, R. Rinze, N. Alp, C. Cunnington, J. Diesch, D. Tousoulis, C. Stefanadis, P. Leeson, et al. Altered Plasma Versus Vascular Biopterins in Human Atherosclerosis Reveal Relationships Between Endothelial Nitric Oxide Synthase Coupling, Endothelial Function, and Inflammation Circulation, December 11, 2007; 116(24): 2851 - 2859. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Widder, W. Chen, L. Li, S. Dikalov, B. Thony, K. Hatakeyama, and D. G. Harrison Regulation of Tetrahydrobiopterin Biosynthesis by Shear Stress Circ. Res., October 12, 2007; 101(8): 830 - 838. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Moens and D. A. Kass Tetrahydrobiopterin and Cardiovascular Disease Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2439 - 2444. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. V. d'Uscio and Z. S. Katusic Increased vascular biosynthesis of tetrahydrobiopterin in apolipoprotein E-deficient mice Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2466 - H2471. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Huang, Y.-Y. Zhang, K. Chen, K. Hatakeyama, and J. F. Keaney Jr Cytokine-Stimulated GTP Cyclohydrolase I Expression in Endothelial Cells Requires Coordinated Activation of Nuclear Factor-{kappa}B and Stat1/Stat3 Circ. Res., February 4, 2005; 96(2): 164 - 171. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Franscini, E. B. Bachli, N. Blau, M.-S. Leikauf, A. Schaffner, and G. Schoedon Gene Expression Profiling of Inflamed Human Endothelial Cells and Influence of Activated Protein C Circulation, November 2, 2004; 110(18): 2903 - 2909. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. S. Katusic and L. V. d'Uscio Tetrahydrobiopterin: Mediator of Endothelial Protection Arterioscler Thromb Vasc Biol, March 1, 2004; 24(3): 397 - 398. [Full Text] |
||||
![]() |
N. J. Alp and K. M. Channon Regulation of Endothelial Nitric Oxide Synthase by Tetrahydrobiopterin in Vascular Disease Arterioscler Thromb Vasc Biol, March 1, 2004; 24(3): 413 - 420. [Abstract] [Full Text] |
||||
![]() |
L. V. d'Uscio, S. Milstien, D. Richardson, L. Smith, and Z. S. Katusic Long-Term Vitamin C Treatment Increases Vascular Tetrahydrobiopterin Levels and Nitric Oxide Synthase Activity Circ. Res., January 10, 2003; 92(1): 88 - 95. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. S. Katusic Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am J Physiol Heart Circ Physiol, September 1, 2001; 281(3): H981 - H986. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Laursen, M. Somers, S. Kurz, L. McCann, A. Warnholtz, B. A. Freeman, M. Tarpey, T. Fukai, and D. G. Harrison Endothelial Regulation of Vasomotion in ApoE-Deficient Mice : Implications for Interactions Between Peroxynitrite and Tetrahydrobiopterin Circulation, March 6, 2001; 103(9): 1282 - 1288. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Johns, A. M. Dorrance, N. L. Tramontini, and R. C. Webb Glucocorticoids Inhibit Tetrahydrobiopterin-Dependent Endothelial Function Experimental Biology and Medicine, January 1, 2001; 226(1): 27 - 31. [Abstract] [Full Text] |
||||
![]() |
L. R. Vann, S. Twitty, S. Spiegel, and S. Milstien Divergence in Regulation of Nitric-oxide Synthase and Its Cofactor Tetrahydrobiopterin by Tumor Necrosis Factor-alpha . CERAMIDE POTENTIATES NITRIC OXIDE SYNTHESIS WITHOUT AFFECTING GTP CYCLOHYDROLASE I ACTIVITY J. Biol. Chem., April 28, 2000; 275(18): 13275 - 13281. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Bhagat, A. D Hingoranil, M. Palacios, I. G Charles, and P. Vallance Cytokine-induced venodilatation in humans in vivo: eNOS masquerading as iNOS Cardiovasc Res, March 1, 1999; 41(3): 754 - 764. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Heller, A. Unbehaun, B. Schellenberg, B. Mayer, G. Werner-Felmayer, and E. R. Werner L-Ascorbic Acid Potentiates Endothelial Nitric Oxide Synthesis via a Chemical Stabilization of Tetrahydrobiopterin J. Biol. Chem., January 5, 2001; 276(1): 40 - 47. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |